Deep Dive: JPM M&A Rush, the start, as Biopharma Insider Mega deals presupposes

While J & J steel the headlines, GSK arrived there first At JPM this year with a advance of 1 billion US dollar for the purchase of the precision therapy specialist IDRX and the rare cancer medication candidate. Eli Lilly also threw down Cool $ 1 billion For the PI3Kα inhibitor program from Scorpion Therapeutics.

Biogen also made an undesirable offer for competitive partner Sage therapeutics, evaluate the biotech of neuroscience at 469 million US dollars that became more complicated Days later when sage sued. This week, sage leaned the undesirable offerA deal deal that you cannot observe this year.

All in all, the transactions at the meeting contributed to bringing a little shine to Biopharma, which usually indicates the sound for the year. I was on site in San Francisco and reported on Biospace about what the Biopharma executives are planning for this year. My conversations with BiogenicPresent Daiichi sankyoPresent BiontechPresent Gilead And Novavax were among the highlights.

JPM is of course also the time for the industry to make theirs Predictions for the year. Managers with whom I predicted the return of M&A to a large extent this year. Mark McKenna, CEO of Mirador Therapeutics, even brave that 2025 will be the year of Megamer. Biopharma returned to the 2019 heyday when $ 60 billion was not unusual.

Biospace In addition, some of their own forecasts, with their picks publishing their picks for Biotech startups. This year we give 25 companies that operate the range of Biopharma innovationFrom ADCs to radiopharmaceuticals to cell and gene therapy and more. At JPM we had the opportunity to meet some of our Star companies to hear what drives them for the industry in this challenging time.

As just one example: neuropsychiatry aligned Seaport therapy The dynamic that started last year is to maintain BMS with the consent of BMS 'schizophrenia -drug -fy from BMS. This drug came from the takeover of Karuna in the amount of almost 9 billion US dollars, whose former managers are now working together in Seaport.

We will have to come more of ours Nextgen class from 2025 in the coming weeks. At JPM I spoke to the Cour Pharmaceuticals, Delphia Therapeutics, Ratio Therapeutics and Mirador. Stay up to date to more content from the Biospace Team.

Note from the publisher: This article was originally published as a special edition of Biopharm Executive. BiospaceThe weekly newsletter on business and financial news. You can Subscribe here.